Allow second Covishield dose after 4 weeks from first: Kerala HC to Centre




The Kerala High Court has directed the Centre to allow scheduling, on CoWIN portal, of second COVISHIELD dose after four weeks from the first for those who want to take it earlier than the present suggested gap of 84 days.


Justice P B Suresh Kumar said that if the central state governments can permit persons traveling abroad to choose between early better protection from COVID-19, there is no reason why the same privilege cannot be extended to those here who want early protection in connection with their employment or education.





The high court, in its order dated September 3 which was made available on Monday, said that even according to the Union Health Ministry’s policy the people shall have the choice to get early vaccination, for the implementation of which vaccine is being distributed on payment basis through private hospitals as well.


“The fourth respondent (Centre) is directed to make necessary provisions forthwith in the CoWIN portal, so as to enable scheduling of second dose of COVISHIELD vaccine after four weeks of the first dose for those who want to accept the second dose after a period of four weeks in terms of the initial protocol of the vaccine,” the court said.


The observations directions of the court came while allowing the plea by Kitex Garments Ltd, represented by advocate Blaze K Jose, seeking permission to administer the second dose of COVISHIELD vaccine to its workers without having to wait for 84 days.


Kitex, in its plea had said that it has already vaccinated more than 5,000 of its workers with the first dose has arranged for the second dose at a cost of nearly Rs 93 lakh, but was unable to administer the same due to the prevailing restrictions.


The Centre had opposed the plea by contending that the 84-day gap between two doses of COVISHIELD was fixed to increase the efficacy of the vaccine, as recommended by the National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) was also based on the technical inputs provided by the National Immunization Technical Advisory Group (NITAG).

(Only the headline picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information commentary on developments that are of interest to you have wider political economic implications for the country the world. Your encouragement constant feedback on how to improve our offering have only made our resolve commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed updated with credible news, authoritative views incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better more relevant content. We believe in free, fair credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism subscribe to Business Standard.

Digital Editor



Source link